Medical Developments International Limited provided earnings guidance for the fiscal year 2022 and revenue guidance for the fiscal year 2023. For the year 2022, the company expects revenue of AUD 22.4 million and EBIT of AUD 15.9 million.

MVP's strong revenue growth trajectory is expected to continue into fiscal year 2023, driven by: significant growth in France; penetration in Australian hospital emergency departments; continued growth in Australian ambulance market; further market share gains in Respiratory segment, primarily in the US; volume growth in distributor markets driven by enhanced distributor engagement; and higher average selling prices driven by growth in direct sales.